Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.7952W HIGH $11.45
Volume
1.31 M
Value Traded
8.54 M
Short % Float
19.55%
-0.44%Week
-28.51%1 Month
-34.55%3 Month
-14.96%6 Month
-88.65%5 Year
-98.27%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
731.28 M
EPS (TTM)
-1.93
P/E Ratio
-
Ent. Value
353.60 M
Total Shares
107.23 M
Float Shares
87.49 M
Insiders
18.41%
Institutions
90.55%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SLDB Catalyst Timeline
Dated clinical, regulatory and corporate events for Solid Biosciences Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Solid Biosciences Inc.
225Total events
6Upcoming
41Tier-1 (high impact)
2017 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Trial InitiationSGT-501Trial
Clinical trial sites activated and participant screening commenced for ARTEMIS
Catecholaminergic polymorphic ventricular tachycardia (CPVT)source ↗
●ATM ProgramCorporate
Additional $15.7 million net proceeds from ATM sales after June 30, 2026
●Enrollment UpdateSGT-003Trial
53 participants dosed in INSPIRE DUCHENNE as of August 4, 2026
Duchenne muscular dystrophysource ↗
●Enrollment UpdateSGT-212Trial
Two participants dosed in FALCON as of August 4, 2026
Friedreich's ataxiasource ↗
▲Enrollment MilestoneSGT-003Trial
53 participants dosed in INSPIRE DUCHENNE
Duchenne muscular dystrophysource ↗
▼ATM ProgramCorporate
ATM sales generated $60.8 million net proceeds in H1 2026 and additional $15.7 million after June 30
◆Oral PresentationSGT-212Presentation
Efficacy and Safety of SGT-212 for Friedreich's Ataxia
Friedreich's Ataxiasource ↗
▲First Patient DosedSGT-003Trial
First participant dosed in Phase 3 IMPACT DUCHENNE trial
Duchenne Muscular Dystrophysource ↗
▲EU Orphan DesignationSGT-003Ex-US Regulatory
Orphan drug designation from European Commission
Duchenne Muscular Dystrophysource ↗
▲EMA PrimeSGT-003Ex-US Regulatory
Positive opinion on Pediatric Investigation Plan from EMA
Duchenne Muscular Dystrophysource ↗
▲First Patient DosedSGT-212Trial
Second participant dosed in Phase 1b FALCON trial
Friedreich's Ataxiasource ↗
▲Enrollment UpdateSGT-003Trial
47 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial
Duchenne Muscular Dystrophysource ↗
◆FDA Feedback ReceivedSGT-003FDA Meeting
Ongoing engagement with FDA for accelerated approval pathway guidance
Duchenne Muscular Dystrophysource ↗
▲MHRA ILAPSGT-003Ex-US Regulatory
Working with MHRA under ILAP Innovation Passport
Duchenne Muscular Dystrophysource ↗
▲First Patient DosedSGT-003Trial
First participant dosed in Phase 3 IMPACT DUCHENNE trial
Duchenne muscular dystrophysource ↗
◆Poster PresentationSGT-501Presentation
Novel AAV Gene Therapy Strategy to Correct Calcium Dysregulation in CPVT
Catecholaminergic Polymorphic Ventricular Tachycardiasource ↗
▲EU Orphan DesignationSGT-003Ex-US Regulatory
European Commission grants Orphan Drug Designation for SGT-003
Duchenne muscular dystrophysource ↗
◆Poster PresentationSGT-212Presentation
Efficacy and Safety of SGT-212 for Friedreich's Ataxia
Friedreich's ataxiasource ↗
▲Type C MeetingSGT-003FDA Meeting
Positive feedback from Type C meeting with FDA on Phase 3 trial design
Duchenne muscular dystrophysource ↗
▲Enrollment UpdateSGT-003Trial
36 participants dosed in Phase 1/2 INSPIRE DUCHENNE as of Feb 9, 2026
Duchenne muscular dystrophysource ↗
▲Orphan Drug DesignationSGT-212Designation
FDA Orphan Drug designation granted to SGT-212
Friedreich's ataxiasource ↗
▲Trial InitiationSGT-501Trial
Clinical trial sites activated for Phase 1b ARTEMIS trial; participant screening underway
Catecholaminergic polymorphic ventricular tachycardiasource ↗
▲Partnership / LicensePOLARIS-101Corporate
Executed 50+ agreements including licenses for AAV-SLB101 capsid
▲Orphan Drug DesignationSGT-212Designation
FDA grants Orphan Drug designation for SGT-212
Friedreich's Ataxiasource ↗
▲First Patient DosedSGT-212Trial
First participant dosed in Phase 1b FALCON trial
Friedreich's Ataxiasource ↗
▲Enrollment MilestoneSGT-003Trial
Dosed 33 participants in Phase 1/2 INSPIRE DUCHENNE trial as of January 9, 2026
Duchenne muscular dystrophysource ↗
◆FDA ApprovalSGT-003FDA Decision
Additional meetings with FDA in 1H 2026 to discuss accelerated approval pathway
Duchenne muscular dystrophysource ↗
▲First Patient DosedSGT-501Trial
First participant dosing anticipated in Phase 1b ARTEMIS trial
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)source ↗
◆Enrollment MilestoneSGT-003Trial
Expect to dose 30 participants total by early 2026
Duchenne muscular dystrophysource ↗
◆FDA Feedback ReceivedSGT-003FDA Meeting
Planned FDA meeting to discuss registrational pathways in H1 2026
Duchenne muscular dystrophysource ↗
●Oral PresentationSGT-501Presentation
Preclinical development presentation for CPVT gene therapy
catecholaminergic polymorphic ventricular tachycardia (CPVT)source ↗
▲Rare Pediatric DiseaseSGT-212Designation
FDA Rare Pediatric Disease designation granted for SGT-212
Friedreich's Ataxiasource ↗
▲Trial InitiationSGT-212Trial
FALCON Phase 1b trial participant screening underway
Friedreich's Ataxiasource ↗
▲Partnership / LicenseCorporate
Non-exclusive worldwide license agreement with Andelyn Biosciences for AAV-SLB101
▲MHRA ILAPSGT-003Ex-US Regulatory
SGT-003 awarded Innovation Passport under UK ILAP
Duchenne muscular dystrophysource ↗
▲Trial InitiationSGT-003Trial
First clinical trial site activated and screening participants for IMPACT DUCHENNE
Duchenne muscular dystrophysource ↗
▲Trial InitiationSGT-003Trial
First clinical trial site activated for IMPACT DUCHENNE
Duchenne muscular dystrophysource ↗
▲Trial InitiationSGT-212Trial
First clinical trial site activated for FALCON
Friedreich's ataxiasource ↗
▲Full ResultsSGT-003Clinical Data
Interim clinical data update with Day 90 and Day 360 biopsy data
Duchenne muscular dystrophysource ↗
Past FDA Catalysts and PDUFA Decisions
How SLDB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-01 | SGT-212 (gene therapy for Friedreich’s ataxia) | Phase 1b data readout | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$77M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.1x
rNPV / MCap
Top 42%
Micro Cap(rank 277 of 658)
Percentile Rank
Solid Biosciences Inc. faces pipeline headwinds (39/100), with $193M risk-adjusted pipeline value, led by SGT-003 in Duchenne Muscular Dystrophy (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SGT-003 Gene therapyNCT06138639 | Duchenne Muscular Dystrophy | Phase 3 | RECRUITING | 140 | May 6, 2031 |
Clinical Trial Results
Readouts, endpoints and source filings for every SLDB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SGT-003 Fast TrackRare Pediatric | Duchenne muscular dystrophy | Phase 1/2 | 2026-01-14 | Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation regimenRead More | Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SMITH IAN FDirector | Option | 3,440 141,585 held | $0.00 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SLDB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 1 % (42.9 %) | 120.24 M | 12.04 M | 28.87% ( 2.70 M) |
SLDB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SLDB ranks across every disease it competes in
Competitive Position is a premium feature
See how SLDB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSLDB News
SLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc. has announced the grant of 8,150 restricted stock units (RSUs) to a newly hired employee as part of its 2024 Inducement Stock Incentive Plan. The RSUs will vest over four years, contingent on the employee's continued service. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent in the field of genetic medicine.
Read more →SLDBSolid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Inc. announced its participation in several upcoming investor conferences, including the Cantor Global Healthcare Conference and the Citi Biopharma Back to School Conference. Key executives will engage in fireside chats to discuss the company's advancements in precision genetic medicines targeting rare neuromuscular and cardiac diseases. Webcasts of these events will be available for investors.
Read more →SLDBSolid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
Solid Biosciences reported its financial results for Q2 2026, highlighting progress in its clinical trials for SGT-003 and SGT-212. The company plans to meet with the FDA to discuss SGT-003's data and potential accelerated approval. Additionally, the Phase 3 IMPACT DUCHENNE trial has commenced, and initial data from the Friedreich's Ataxia trial is anticipated in early 2027. Despite a growing cash position, the company reported a net loss of $54.8 million for the quarter.
Read more →SLDB▼ -8.5%on this news
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 1, 2026
Solid Biosciences Inc. has announced the grant of 6,580 restricted stock units (RSUs) to a newly hired employee. This grant is part of the company's 2024 Inducement Stock Incentive Plan and is intended to incentivize the employee's acceptance of the job. The RSUs will vest over four years, contingent on the employee's continued service.
Read more →SLDBSolid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
Solid Biosciences reported its Q1 2026 financial results, highlighting significant advancements in its clinical trials for Duchenne muscular dystrophy and Friedreich's ataxia. The company has initiated the Phase 3 IMPACT DUCHENNE trial and received positive regulatory feedback from the EMA. Additionally, Solid maintains a robust cash position, supporting its ongoing development efforts.
Read more →SLDBSolid Biosciences Doses First Participant In Phase 3 Impact Duchenne Clinical Trial Evaluating SGT-003 In Duchenne Muscular Dystrophy
Solid Biosciences Doses First Participant In Phase 3 Impact Duchenne Clinical Trial Evaluating SGT-003 In Duchenne Muscular Dystrophy
Read more →SLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Solid Biosciences Inc. has announced the grant of 8,070 restricted stock units to a newly hired employee as part of its 2024 Inducement Stock Incentive Plan. This grant, which vests over four years, is intended to incentivize the new employee's acceptance of the position. The company continues to advance its pipeline of gene therapies targeting rare neuromuscular and cardiac diseases.
Read more →SLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4
Read more →SLDBSolid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
Solid Biosciences Inc. will present its largest scientific program at the 29th Annual Meeting of the ASGCT, featuring 16 presentations including 5 oral and 11 poster presentations. The event highlights the company's advancements in gene therapies for neuromuscular and cardiac diseases, showcasing their commitment to innovation and clinical development. CEO Bo Cumbo emphasized the significance of this meeting for Solid's growth and scientific rigor.
Read more →SLDBSolid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
Solid Biosciences has announced that the European Commission granted Orphan Drug Designation for SGT-003, aimed at treating Duchenne muscular dystrophy. This designation reflects the drug's potential to address significant unmet medical needs. SGT-003 is currently being evaluated in two clinical trials, INSPIRE DUCHENNE and IMPACT DUCHENNE, as part of a broader international development strategy.
Read more →SLDBSolid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Read more →SLDB▼ -5.7%on this news
Solid Biosciences Provides Interim Positive Clinical Update
Solid Biosciences has reported positive interim results from its Phase 1/2 INSPIRE DUCHENNE trial of SGT-003, a gene therapy for Duchenne muscular dystrophy. Key findings include robust microdystrophin expression and improvements in muscle integrity and cardiac function among the 40 participants dosed. The company plans to engage with the FDA regarding a potential accelerated approval pathway for SGT-003.
Read more →SLDB▲ +18.8%on this newsshared move
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Solid Biosciences Inc. will present its investigational gene therapies SGT-003 and SGT-212 at the 2026 MDA Clinical & Scientific Conference in Orlando. The presentations will cover the Phase 1/2 study of SGT-003 for Duchenne muscular dystrophy and the investigational gene therapy SGT-212 for Friedreich’s ataxia. The conference will take place from March 8-11, 2026.
Read more →SLDB▲ +18.8%on this newsshared move
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
Solid Biosciences Inc. has announced a successful oversubscribed private placement, raising approximately $240 million from institutional investors. The financing will close on or about March 9, 2026, and will be used to advance the company's pipeline of genetic medicines targeting neuromuscular and cardiac diseases. The placement was priced to meet Nasdaq's minimum price requirement.
Read more →SLDB▲ +20.3%on this news· ran to +43% by day 1shared move
Solid Biosciences Announces Oversubscribed 240 Million Private Placement
Solid Biosciences Announces Oversubscribed 240 Million Private Placement
Read more →SLDB▲ +20.3%on this news· ran to +43% by day 1shared move
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association MDA Clinical Scientific Conference
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association MDA Clinical Scientific Conference
Read more →SLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 2, 2026
Solid Biosciences Inc. has announced the grant of 17,600 restricted stock units (RSUs) to a newly hired employee, as part of its 2024 Inducement Stock Incentive Plan. The RSUs will vest over four years, contingent on the employee's continued service. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and underscores the company's commitment to attracting skilled professionals in the field of genetic medicine.
Read more →SLDB▲ +5.2%on this news
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
Solid Biosciences has received positive feedback from the FDA regarding the design of its Phase 3 trial for SGT-003, a gene therapy for Duchenne muscular dystrophy. The trial, named IMPACT DUCHENNE, is set to begin participant dosing in Q1 2026. The company is also planning further discussions with the FDA to explore an accelerated approval pathway. The ongoing Phase 1/2 trial has shown SGT-003 to be generally well tolerated among participants.
Read more →About Solid Biosciences Inc.
Headquarters500 RUTHERFORD AVENUE, CHARLESTOWN, MA, 02129
BIOPHARMAWATCH ELITE PLUS
Trade the next SLDB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime